MX373176B - Donadores de nitroxilo con indice terapeutico mejorado. - Google Patents

Donadores de nitroxilo con indice terapeutico mejorado.

Info

Publication number
MX373176B
MX373176B MX2015009276A MX2015009276A MX373176B MX 373176 B MX373176 B MX 373176B MX 2015009276 A MX2015009276 A MX 2015009276A MX 2015009276 A MX2015009276 A MX 2015009276A MX 373176 B MX373176 B MX 373176B
Authority
MX
Mexico
Prior art keywords
therapeutic index
improved therapeutic
compounds
nitroxyl donors
pharmaceutical compositions
Prior art date
Application number
MX2015009276A
Other languages
English (en)
Spanish (es)
Other versions
MX2015009276A (es
Inventor
Frederick Arthur Brookfield
John P Toscano
Lisa Marie Frost
Stephen Martin Courtney
Vincent Jacob Kalish
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of MX2015009276A publication Critical patent/MX2015009276A/es
Publication of MX373176B publication Critical patent/MX373176B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015009276A 2013-01-18 2014-01-17 Donadores de nitroxilo con indice terapeutico mejorado. MX373176B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
PCT/US2014/012085 WO2014113696A1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index

Publications (2)

Publication Number Publication Date
MX2015009276A MX2015009276A (es) 2015-10-30
MX373176B true MX373176B (es) 2020-04-22

Family

ID=50064795

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009276A MX373176B (es) 2013-01-18 2014-01-17 Donadores de nitroxilo con indice terapeutico mejorado.
MX2015009269A MX363843B (es) 2013-01-18 2014-01-17 Composiciones farmaceuticas que comprenden donadores de nitroxilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015009269A MX363843B (es) 2013-01-18 2014-01-17 Composiciones farmaceuticas que comprenden donadores de nitroxilo.

Country Status (29)

Country Link
US (13) US8987326B2 (enExample)
EP (5) EP3567031A1 (enExample)
JP (5) JP6533159B2 (enExample)
KR (2) KR102277165B1 (enExample)
CN (4) CN110179777B (enExample)
AU (5) AU2014207404B2 (enExample)
BR (2) BR112015017251B1 (enExample)
CA (2) CA2898443C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK2945620T3 (enExample)
ES (4) ES2705240T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20180121T1 (enExample)
HU (3) HUE041861T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT2945621T (enExample)
MX (2) MX373176B (enExample)
NZ (4) NZ709986A (enExample)
PL (3) PL3284463T3 (enExample)
PT (3) PT2945621T (enExample)
RS (3) RS59434B1 (enExample)
RU (3) RU2676277C2 (enExample)
SG (6) SG10201802862WA (enExample)
SI (3) SI3284463T1 (enExample)
SM (3) SMT201800088T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI619491B (enExample)
WO (2) WO2014113696A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708804B8 (pt) 2006-03-17 2021-05-25 Cardioxyl Pharmaceuticals Inc compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit
AU2013201929B2 (en) 2011-10-17 2015-07-23 The Johns Hopkins University N-substituted hydroxylamine derivatives with carbon-based leaving groups
TWI619491B (zh) 2013-01-18 2018-04-01 卡爾迪奧克斯爾製藥公司 包含硝醯基予體的醫藥組合物
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
CN108349911B (zh) 2015-09-07 2022-05-13 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
JP6957459B2 (ja) 2015-10-19 2021-11-02 カルディオキシル ファーマシューティカルズ，インク． ニトロキシルドナーとしてのｎ−ヒドロキシルスルホンアミド誘導体
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10913728B2 (en) 2016-07-28 2021-02-09 The Johns Hopkins University O-substituted hydroxamic acids
WO2018128999A1 (en) * 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
WO1995019952A1 (de) * 1994-01-19 1995-07-27 Byk Nederland Bv Nitroxy-gruppen enthaltende benzylaminderivate und ihre verwendung zur behandlung von cardiovasculären erkrankungen sowie erhöhtem augeninnendruck
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
KR20010031319A (ko) 1997-10-24 2001-04-16 요시히코 시오노 항류마티스제
EP0930302B1 (en) * 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Benzosulfone derivatives
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
NZ538100A (en) * 2000-12-13 2006-07-28 Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090281067A1 (en) 2004-01-30 2009-11-12 The John Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
BRPI0708804B8 (pt) 2006-03-17 2021-05-25 Cardioxyl Pharmaceuticals Inc compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
SG185255A1 (en) 2007-09-26 2012-11-29 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
JP5654450B2 (ja) 2008-05-07 2015-01-14 カルディオキシル ファーマシューティカルズ，インク． ニトロキシル供与体としての新規ニトロソ化合物およびその使用方法
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN105919987B (zh) 2009-12-07 2020-04-03 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物及其用途
MX356796B (es) 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
AU2013201929B2 (en) 2011-10-17 2015-07-23 The Johns Hopkins University N-substituted hydroxylamine derivatives with carbon-based leaving groups
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
TWI619491B (zh) * 2013-01-18 2018-04-01 卡爾迪奧克斯爾製藥公司 包含硝醯基予體的醫藥組合物
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
IL239952B (en) 2018-05-31
MX2015009276A (es) 2015-10-30
IL239906B (en) 2018-05-31
PT3284463T (pt) 2019-10-30
WO2014113700A1 (en) 2014-07-24
AU2014207404A1 (en) 2015-08-13
BR112015017241A2 (pt) 2017-07-11
HUE036589T2 (hu) 2018-07-30
NZ748769A (en) 2020-05-29
TWI619491B (zh) 2018-04-01
US20190224159A1 (en) 2019-07-25
AU2014207408A8 (en) 2015-08-27
HRP20191919T8 (hr) 2021-10-01
DK2945621T3 (en) 2019-02-11
AU2017200147B2 (en) 2018-07-05
CY1120535T1 (el) 2019-07-10
ES2659969T3 (es) 2018-03-20
LT2945620T (lt) 2018-02-12
CN110179777A (zh) 2019-08-30
RU2015134583A (ru) 2017-02-22
AU2014207404B2 (en) 2017-10-19
SG11201505567RA (en) 2015-09-29
NZ748771A (en) 2019-12-20
US20150175566A1 (en) 2015-06-25
RU2684916C2 (ru) 2019-04-16
JP6449171B2 (ja) 2019-01-09
US20200121633A1 (en) 2020-04-23
BR112015017241A8 (pt) 2019-10-29
US20240066002A1 (en) 2024-02-29
CN108610312A (zh) 2018-10-02
AU2018241168A1 (en) 2018-11-01
KR102177899B1 (ko) 2020-11-12
PT2945621T (pt) 2019-01-21
HRP20191919T1 (hr) 2020-01-10
AU2018241168B2 (en) 2020-04-02
HRP20180121T1 (hr) 2018-02-23
JP2017125015A (ja) 2017-07-20
DK3284463T3 (da) 2019-10-28
BR112015017251B1 (pt) 2021-10-26
US9156804B2 (en) 2015-10-13
IL259233B (en) 2019-10-31
KR20150107853A (ko) 2015-09-23
WO2014113696A1 (en) 2014-07-24
JP6801045B2 (ja) 2020-12-16
CA2898443C (en) 2022-05-31
US10517847B2 (en) 2019-12-31
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
ES2751922T3 (es) 2020-04-02
AU2014207408C1 (en) 2018-09-06
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
SG10201913286PA (en) 2020-02-27
EP2945620A1 (en) 2015-11-25
BR112015017251A8 (pt) 2019-10-29
SG10201802855TA (en) 2018-05-30
CN105073105A (zh) 2015-11-18
IL258882A (en) 2018-06-28
CN105073105B (zh) 2018-02-27
PL3284463T3 (pl) 2019-12-31
SI2945620T1 (en) 2018-01-31
HUE046722T2 (hu) 2020-03-30
LT2945621T (lt) 2019-01-10
CA2898445A1 (en) 2014-07-24
SI3284463T1 (sl) 2019-12-31
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
US20190133990A1 (en) 2019-05-09
US10245249B2 (en) 2019-04-02
JP2019089764A (ja) 2019-06-13
US20140206769A1 (en) 2014-07-24
US10792273B2 (en) 2020-10-06
EP3284463A1 (en) 2018-02-21
IL239952A0 (en) 2015-08-31
JP2016510326A (ja) 2016-04-07
US10213408B2 (en) 2019-02-26
IL239906A0 (en) 2015-08-31
TW201442702A (zh) 2014-11-16
ZA201604798B (en) 2018-01-31
TW201934120A (zh) 2019-09-01
SMT201800088T1 (it) 2018-03-08
US20220193026A1 (en) 2022-06-23
US8987326B2 (en) 2015-03-24
HK1251170B (en) 2020-04-09
US20200163929A1 (en) 2020-05-28
RS59434B1 (sr) 2019-11-29
CY1122177T1 (el) 2020-11-25
SMT201900027T1 (it) 2019-02-28
CA2898443A1 (en) 2014-07-24
EP3427728A1 (en) 2019-01-16
TWI686193B (zh) 2020-03-01
AU2014207408A1 (en) 2015-08-13
IL259233A (en) 2018-07-31
JP2016505044A (ja) 2016-02-18
ES2882279T3 (es) 2021-12-01
TW201446242A (zh) 2014-12-16
RU2676277C2 (ru) 2018-12-27
HUE041861T2 (hu) 2019-06-28
DK2945620T3 (en) 2018-02-05
US10548872B2 (en) 2020-02-04
PL2945620T3 (pl) 2018-03-30
JP6533159B2 (ja) 2019-06-19
RS58174B1 (sr) 2019-03-29
MX363843B (es) 2019-04-05
BR112015017251A2 (pt) 2017-07-11
NZ709986A (en) 2020-01-31
JP6656345B2 (ja) 2020-03-04
KR102277165B1 (ko) 2021-07-14
US20210015784A1 (en) 2021-01-21
ES2705240T3 (es) 2019-03-22
CY1121480T1 (el) 2020-05-29
EP3284463B1 (en) 2019-07-24
CA2898445C (en) 2022-05-03
JP6311038B2 (ja) 2018-04-11
US9586896B2 (en) 2017-03-07
CN105142627A (zh) 2015-12-09
HRP20182144T1 (hr) 2019-03-08
HK1216858A1 (en) 2016-12-09
WO2014113700A9 (en) 2014-10-09
PL2945621T3 (pl) 2019-05-31
AU2018203240B2 (en) 2019-12-12
TR201802211T4 (tr) 2018-03-21
SI2945621T1 (sl) 2019-01-31
AU2014207408B2 (en) 2018-03-01
JP2019172682A (ja) 2019-10-10
EP3567031A1 (en) 2019-11-13
KR20150108879A (ko) 2015-09-30
TWI712409B (zh) 2020-12-11
HK1216857A1 (en) 2016-12-09
EP3427728B1 (en) 2021-07-07
US11786501B2 (en) 2023-10-17
CN105142627B (zh) 2019-06-21
RU2018143994A (ru) 2019-01-16
SG10201913441RA (en) 2020-03-30
MX2015009269A (es) 2015-10-30
ZA201505090B (en) 2016-10-26
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
PT2945620T (pt) 2018-02-21
US9968584B2 (en) 2018-05-15
CN110179777B (zh) 2022-07-15
AU2017200147A1 (en) 2017-02-02
SG10201802862WA (en) 2018-05-30
BR112015017241B1 (pt) 2021-10-26
US11273143B2 (en) 2022-03-15
AU2018203240A1 (en) 2018-05-31
LT3284463T (lt) 2019-11-11
US20170151210A1 (en) 2017-06-01
US20180235927A1 (en) 2018-08-23
SMT201900575T1 (it) 2019-11-13
NZ709985A (en) 2020-05-29
US12186301B2 (en) 2025-01-07
EP2945620B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
MX373176B (es) Donadores de nitroxilo con indice terapeutico mejorado.
MX2016002571A (es) Regulador de ph de transduccion.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
MX378273B (es) Compuestos activos hacia bromodominios.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA202193044A2 (ru) Способы лечения таупатии
EA201591748A1 (ru) Модуляторы p2x7
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX2016000997A (es) Metodos y composiciones para detectar contaminacion bacteriana.
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2020002544A (es) Sales de glicopirrolato.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
MX373308B (es) Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"

Legal Events

Date Code Title Description
FG Grant or registration